AstraZeneca (AZN) Pharma and Biotech Sector

  • Latest quote

    5,162.00p (mid)

  • Current Change (%)

    -0.23%

  • Price

    Bid: 5,162.00p

    Offer: 5,163.00p

  • Today

    High: 5,199.00p

    Low: 5,159.00p

  • This year

    High: 5,508.00p

    Low: 4,007.00p

  • Information

    Volume: 1,077,116

    Market Cap: £65311.95M


AstraZeneca RNS Feed

Title Release date
FDA Priority Review for Lynparza in breast cancer 07:00 - October 18, 2017
FDA accepts sBLA file for Imfinzi; priority review 07:00 - October 17, 2017
FDA grants Tagrisso BTD for 1st-line EGFR nsclc 07:00 - October 9, 2017
Total Voting Rights 15:00 - October 2, 2017
Director/PDMR Shareholding 12:00 - September 26, 2017
Aspen acquires remaining rights to AZ anaesthetics 07:00 - September 14, 2017
IMFINZI superior PFS in Stage III lung cancer 07:00 - September 11, 2017
Tagrisso potential standard of care in lung cancer 07:00 - September 11, 2017
Celgene and AZ update on Fusion trial programme 12:39 - September 7, 2017
AZ tezepelumab cuts exacerbations in severe asthma 07:00 - September 7, 2017
AZ Duaklir improves lung function in COPD patients 07:00 - September 7, 2017
Directorate Change 07:00 - September 5, 2017
Total Voting Rights 15:00 - September 1, 2017
Lynparza gets broad FDA approval in ovarian cancer 07:00 - August 18, 2017
Directorate Change 07:00 - August 16, 2017

NOTE: This is based on 286 open tips for this company


Total Number of Share tips :

286

View all AstraZeneca Tips


Company overview

A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium.

Daily share tips delivered straight to your pc, tablet & mobile

Join Free Today